0001839882-22-021300.txt : 20220923 0001839882-22-021300.hdr.sgml : 20220923 20220923170636 ACCESSION NUMBER: 0001839882-22-021300 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220923 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220923 DATE AS OF CHANGE: 20220923 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Adamis Pharmaceuticals Corp CENTRAL INDEX KEY: 0000887247 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 820429727 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36242 FILM NUMBER: 221262941 BUSINESS ADDRESS: STREET 1: 11682 EL CAMINO REAL STREET 2: SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 997-2400 MAIL ADDRESS: STREET 1: 11682 EL CAMINO REAL STREET 2: SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92130 FORMER COMPANY: FORMER CONFORMED NAME: CELLEGY PHARMACEUTICALS INC DATE OF NAME CHANGE: 19950615 8-K 1 admp-8k_092322.htm CURRENT REPORT
0000887247 false 0000887247 2022-09-23 2022-09-23 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): September 23, 2022

 

ADAMIS PHARMACEUTICALS CORPORATION

(Exact Name of Registrant as Specified in Charter)

 

Delaware   0-26372   82-0429727

(State or other jurisdiction of incorporation)

  (Commission File Number)  

(IRS Employer Identification No.)

 

11682 El Camino Real, Suite 300

San Diego, CA

  92130
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (858) 997-2400

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

  Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock   ADMP   NASDAQ Capital Market

 

 

 

 

 

 

 

Item 8.01 Other Events.

On September 23, 2022, Adamis Pharmaceuticals Corporation (the “Company”) filed with the Securities and Exchange Commission (the “Commission”) a prospectus supplement dated September 23, 2022 (the “Prospectus Supplement”), pursuant to Rule 424(b) under the Securities Act of 1933, as amended. The Prospectus Supplement was filed pursuant to the Company’s effective shelf registration statement on Form S-3 (Registration No. 333-267365), filed with the Commission on September 9, 2022. The Prospectus Supplement was filed to register the issuance and sale by the Company from time to time of up to 13,794,000 shares of the Company’s common stock issuable upon the exercise of certain outstanding warrants.

Item 9.01 Financial Statement and Exhibits.

(d) Exhibits.

Exhibit
No.
  Description
   
5.1   Opinion of Latham & Watkins, LLP
23.1   Consent of Latham & Watkins, LLP (included in Exhibit 5.1)
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  ADAMIS PHARMACEUTICALS CORPORATION
     
     
Dated:  September 23, 2022 By: /s/ David C. Benedicto
  Name: David C. Benedicto
  Title: Chief Financial Officer

 

 

EX-5.1 2 ex5-1.htm OPINION OF LATHAM & WATKINS, LLP

 

Adamis Pharmaceuticals Corporation 8-K

Exhibit 5.1

 

12670 High Bluff Drive

San Diego, California 92130

Tel: +1.858.523.5400 Fax: +1.858.523.5450

www.lw.com

 

FIRM / AFFILIATE OFFICES

  Austin Milan
  Beijing Munich
  Boston New York
  Brussels Orange County
  Century City Paris
  Chicago Riyadh

September 23, 2022

Dubai San Diego
  Düsseldorf San Francisco
  Frankfurt Seoul
  Hamburg Shanghai
  Hong Kong Silicon Valley
  Houston Singapore
  London Tel Aviv
  Los Angeles Tokyo
  Madrid Washington, D.C.

 

 

Adamis Pharmaceuticals Corporation

11682 El Camino Real, Suite 300

San Diego, California 92130

 

Re:Registration Statement on Form S-3

 

To the addressees set forth above:

We have acted as special counsel to Adamis Pharmaceuticals Corporation, a Delaware corporation (the “Company”), in connection with its filing on the date hereof with the Securities and Exchange Commission (the “Commission”) of a Prospectus Supplement (as defined below) relating to the registration for issuance and sale by the Company from time to time of up to 13,794,000 shares (the “Warrant Shares”) of the Company’s common stock, par value $0.001 per share, issuable upon exercise of outstanding warrants (the “Warrants”). The issuance and sale of the Warrant Shares is being registered pursuant to a registration statement on Form S-3 (the “Registration Statement”), under the Securities Act of 1933, as amended (the “Act”), filed with the Commission on September 9, 2022 (Registration No. 333- 267365), including a base prospectus dated September 19, 2022, included in the Registration Statement at the time it originally became effective (the “Base Prospectus”), and a prospectus supplement dated September 23, 2022, filed with the Commission pursuant to Rule 424(b) under the Act (the “Prospectus Supplement” and, together with the Base Prospectus, the “Prospectus”).

This opinion is being furnished in connection with the requirements of Item 601(b)(5) of Regulation S-K under the Act, and no opinion is expressed herein as to any matter pertaining to the contents of the Registration Statement or related applicable Prospectus, other than as expressly stated herein with respect to the Warrants and the issue of the Warrant Shares.

As such counsel, we have examined such matters of fact and questions of law as we have considered appropriate for purposes of this letter. With your consent, we have relied upon certificates and other assurances of officers of the Company and others as to factual matters without having independently verified such factual matters. We are opining herein as to the General Corporation Law of the State of Delaware (the “DGCL”) and we express no opinion with respect to the applicability thereto, or the effect thereon, of the laws of any other jurisdiction or, in the case of Delaware, any other laws, or as to any matters of municipal law or the laws of any local agencies within any state.

 

September 23, 2022

Page 2

 

 

Subject to the foregoing and the other matters set forth herein, it is our opinion that, as of the date hereof;

1.       

The Warrants have been duly authorized, executed and delivered by the Company and the Warrants constitute legally valid and binding obligations of the Company, enforceable against the Company in accordance with their terms.

2.       

The issue and sale of the Warrant Shares in the manner contemplated by the Prospectus Supplement and the Warrants have been duly authorized by all necessary corporate action of the Company, and upon issuance and delivery thereof and payment therefor in the manner contemplated by the Prospectus Supplement and the Warrants, the Warrant Shares will be validly issued, fully paid and nonassessable. In rendering the foregoing opinion, we have assumed that the Company will comply with all applicable notice requirements regarding uncertificated shares provided in the DGCL.

Our opinions are subject to: (i) the effects of bankruptcy, insolvency, reorganization, preference, fraudulent transfer, moratorium or other similar laws relating to or affecting the rights and remedies of creditors; (ii) the effects of general principles of equity, whether considered in a proceeding in equity or at law (including the possible unavailability of specific performance or injunctive relief), concepts of materiality, reasonableness, good faith and fair dealing, and the discretion of the court before which a proceeding is brought; (iii) the invalidity under certain circumstances under law or court decisions of provisions providing for the indemnification of or contribution to a party with respect to a liability where such indemnification or contribution is contrary to public policy; and (iv) we express no opinion as to (a) any provision for liquidated damages, default interest, late charges, monetary penalties, make-whole premiums or other economic remedies to the extent such provisions are deemed to constitute a penalty, (b) consents to, or restrictions upon, governing law, jurisdiction, venue, arbitration, remedies or judicial relief, (c) waivers of rights or defenses, (d) any provision requiring the payment of attorneys’ fees, where such payment is contrary to law or public policy, (e) any provision permitting, upon acceleration of any debt securities, collection of that portion of the stated principal amount thereof which might be determined to constitute unearned interest thereon, (f) the creation, validity, attachment, perfection, or priority of any lien or security interest, (g) advance waivers of claims, defenses, rights granted by law, or notice, opportunity for hearing, evidentiary requirements, statutes of limitation, trial by jury or at law, or other procedural rights, (h) waivers of broadly or vaguely stated rights, (i) provisions for exclusivity, election or cumulation of rights or remedies, (j) provisions authorizing or validating conclusive or discretionary determinations, (k) grants of setoff rights, (l) proxies, powers and trusts, (m) provisions prohibiting, restricting, or requiring consent to assignment or transfer of any right or property, (n) any provision to the extent it requires that a claim with respect to a security denominated in other than U.S. dollars (or a judgment in respect of such a claim) be converted into U.S. dollars at a rate of exchange at a particular date, to the extent applicable law otherwise provides, and (o) the severability, if invalid, of provisions to the foregoing effect.

With your consent, we have assumed that the status of the Warrants as legally valid and binding obligations of the Company is not affected by any (i) breaches of, or defaults under, agreements or instruments, (ii) violations of statutes, rules, regulations or court or governmental orders, or (iii) failures to obtain required consents, approvals or authorizations from, or make required registrations, declarations or filings with, governmental authorities.

 

September 23, 2022

Page 3

 

 

This opinion is for your benefit in connection with the Registration Statement and may be relied upon by you and by persons entitled to rely upon it pursuant to the applicable provisions of the Act. We consent to your filing this opinion as an exhibit to the Company’s Current Report on Form 8-K dated September 23, 2022 and to the reference to our firm contained in the Prospectus under the heading “Legal Matters.” We further consent to the incorporation by reference of this letter and consent into any registration statement or post-effective amendment to the Registration Statement filed pursuant to Rule 462(b) under the Act with respect to the Warrant Shares. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Act or the rules and regulations of the Commission thereunder.

Sincerely,

 

/s/ Latham & Watkins LLP

 

 

 

EX-101.SCH 3 admp-20220923.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 admp-20220923_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 admp-20220923_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 6 admp_001.jpg GRAPHIC begin 644 admp_001.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Cover
Sep. 23, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Sep. 23, 2022
Entity File Number 0-26372
Entity Registrant Name ADAMIS PHARMACEUTICALS CORPORATION
Entity Central Index Key 0000887247
Entity Tax Identification Number 82-0429727
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 11682 El Camino Real
Entity Address, Address Line Two Suite 300
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92130
City Area Code (858)
Local Phone Number 997-2400
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol ADMP
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 admp-8k_092322_htm.xml IDEA: XBRL DOCUMENT 0000887247 2022-09-23 2022-09-23 iso4217:USD shares iso4217:USD shares 0000887247 false 8-K 2022-09-23 ADAMIS PHARMACEUTICALS CORPORATION DE 0-26372 82-0429727 11682 El Camino Real Suite 300 San Diego CA 92130 (858) 997-2400 false false false false false Common Stock ADMP NASDAQ EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://adamispharmaceuticals.com/role/Cover Cover Cover 1 false false All Reports Book All Reports admp-8k_092322.htm admp-20220923.xsd admp-20220923_lab.xml admp-20220923_pre.xml ex5-1.htm http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "admp-8k_092322.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "admp-8k_092322.htm" ] }, "labelLink": { "local": [ "admp-20220923_lab.xml" ] }, "presentationLink": { "local": [ "admp-20220923_pre.xml" ] }, "schema": { "local": [ "admp-20220923.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "ADMP", "nsuri": "http://adamispharmaceuticals.com/20220923", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "admp-8k_092322.htm", "contextRef": "From2022-09-23to2022-09-23", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://adamispharmaceuticals.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "admp-8k_092322.htm", "contextRef": "From2022-09-23to2022-09-23", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 15 0001839882-22-021300-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001839882-22-021300-xbrl.zip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end